Heyuan Biosciences (688765.SH) is a national high-tech enterprise specializing in the research and development of plant-derived recombinant protein expression technologies and related products. The company is led by a scientific team headed by Professor Yang Daichang. Its core product, the plant-derived recombinant human serum albumin injection HY1001, is the world's first recombinant human albumin drug approved for market utilizing a plant-based expression system. On October 28, 2025, Heyuan Biosciences was listed on the STAR Market. Efung Capital invested in the company twice, in 2016 and 2018.